The amount of governmental money put into dementia and stroke research in the UK has risen significantly in recent years, but is still too low when compared with the economic and personal impact these conditions have, a study published in BMJ Open has found.
Researchers from the University of Oxford assessed governmental and charity research expenditure in 2012 into the UK’s leading causes of death and disability: cancer, coronary heart disease, dementia and stroke.
In 2012, all four conditions accounted for over half (55%) of all UK deaths and for 5.5 million disability adjusted life years (DALYs), which combine the number of years of life lost as a result of early death, and the number of years lost due to ill-health or disability.
The amount of research funding was compared with the population impact of the individual conditions: prevalence, the number of years lost due to early death, ill-health or disability, and the respective total health and social care costs.
The combined amount of research funding allocated by the government and charities to all four conditions came to £856 million in 2012, almost two thirds of which (64%; £544 million) was allocated to cancer. Around one fifth (19%; £166 million) was devoted to coronary heart disease, while just 11% (£90 million) was allocated to dementia and even less (7%; £56 million) to stroke research.
That same year, there were around 2.3 million cases of cancer, the same number of coronary heart disease cases, 0.8 million cases of dementia and 1.2 million of stroke. In 2012 a total of 2.9 million DALYs were lost to cancer, 1.5 million to coronary heart disease, 0.4 million to dementia and 0.7 million to stroke.
The costs of healthcare were highest for cancer (£4.4 billion) and lowest for dementia at £1.4 billion and for stroke at £1.8 billion. But the social care costs of dementia outweighed the social care costs of the other three conditions combined. And the combined costs of health and social care for dementia came to £11.6 billion in 2012, the researchers calculated. This was more than double the equivalent costs for cancer at £5 billion, and significantly more than for stroke (£2.9 billion) and coronary heart disease (£2.5 billion).
This means that for every £10 of health and social care costs attributable to each condition, £1.08 in research funding was spent on cancer, £0.65 on coronary heart disease, £0.19 on stroke, and just £0.08 on dementia, the researchers calculated.
Since 2010, there have been substantial changes in medical research funding policies, particularly by governmental organisations, which pumped 21% of the total share into dementia research and 12% into stroke research in 2012, with cancer attracting 46% of the total spend. The equivalent figures in 2008 were 66% for cancer, 21% for coronary heart disease, 9% for dementia, and just 4% for stroke.
But the sums allocated by charities have scarcely changed since 2008, say the researchers. Charities are reliant on public funds so this stasis may be down to public perception of risk or a form of ageism, derived from the belief that stroke and dementia are inevitable only in the elderly, they suggest.
Professor Alastair Gray of Oxford University's Health Economics Research Centre, senior author of the study, said: 'There has been much progress by governmental research organisations into funding for dementia and stroke but more is needed. Research into the treatment and prevention of dementia and stroke remain underfunded when compared with the economic and personal impact these conditions have.'
A report of the research, entitled 'UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia', is published in BMJ Open.